Analyze Your Search

Hints:

  • Action links for each search result record
    • Bookmark: Allows you to Bookmark the page for easy future retrieval 
    • Email: Opens a pop-up window where you can write a message to the recipient of the email
    • Copy URL: Copies the URL of the requested document for pasting in an email or other document
    • More Info: Shows full summary of content record
  • Saved Searches and Alerts
    • Save your search for later viewing & updates by clicking the blue "Follow" button to the right of the search box. 
Melanoma
  Follow Topic   Edit Search
Your search returned 6 results
from the time period: last 30 days.
Sort by Relevance / Date Group By Journal / No Grouping
The New England journal of medicine 
... the MEK inhibitor trametinib improved survival in patients with advanced melanoma with BRAF V600 mutations... trametinib would improve outcomes in patients with resected, stage III melanoma with BRAF V600 mutations... we randomly assigned 870 patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations to receive oral dabrafenib ...
Oncology (8)
Melanoma (6), more mentions
The New England journal of medicine 
... inhibitors that have been approved for the treatment of advanced melanoma... States, ipilimumab has also been approved as adjuvant therapy for melanoma on the basis of recurrence-free and overall survival rates ... versus ipilimumab for adjuvant therapy in patients with resected advanced melanoma... were undergoing complete resection of stage IIIB, IIIC, or IV melanoma to receive an intravenous infusion of either nivolumab at a ...
Oncology (6)
Melanoma (6), more mentions
The New England journal of medicine 
... ipilimumab alone in a phase 3 trial involving patients with advanced melanoma... in a 1:1:1 ratio, patients with previously untreated advanced melanoma to receive nivolumab at a dose of 1 mg per kilogram ... Conclusions Among patients with advanced melanoma, significantly longer overall survival occurred with combination therapy with nivolumab plus ...
Oncology (5)
Melanoma (4), more mentions
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 
Abstract: Purpose Approximately 40% of patients with advanced melanoma who received nivolumab combined with ipilimumab in clinical trials discontinued treatment because of adverse events (AEs. We conducted a retrospective analysis to assess the efficacy and safety of nivolumab plus ipilimumab in patients who discontinued treatment because of AEs. Methods Data were pooled from phase II and III trials of patients ...
Oncology (2)
Melanoma (2), more mentions
Journal of the American Academy of Dermatology 
Abstract: The reported prevalence of nevus-associated melanoma varies substantially... Any given melanoma was 64% less likely to be nevus-associated than de ... CI] 0.29-0.44; P < .001; I(2) = 99%); nevus-associated melanomas had a lower mean Breslow thickness than de novo melanomas (mean difference -0.39 mm; 95% CI -0.60 to -0.18; P ...
Oncology (4)
Nevus (9), Melanoma (8), Dysplastic Nevi (2), more mentions
Journal of hematology & oncology 
AbstractText: A 31-gene expression profile (GEP) test that provides risk classification of cutaneous melanoma (CM) patients has been validated in several retrospective studies... GEP testing complements current clinicopathologic features and increases identification of high-risk patients AbstractText: ClinicalTrials.gov, NCT02355574 and NCT02355587 Keyword: Cutaneous melanoma. Keyword: DecisionDx-Melanoma. Keyword: Gene expression profiling.
Oncology (7)
Melanoma (4), Neoplasms (1), more mentions